MD Anderson Launches Psilocybin Trial for Chemotherapy Neurotoxicity

MD Anderson to Trial Psilocybin for Chemotherapy-Induced Neurotoxicity

MD Anderson Cancer Center, one of the United States' leading oncology hospitals, is preparing to launch a clinical trial investigating psilocybin's potential to prevent or reduce neurotoxicity caused by chemotherapy. This initiative, announced in September 2026, represents a notable shift in the application of psychedelic compounds, moving beyond psychiatric and end-of-life care into supportive oncology. The trial is expected to enroll patients undergoing neurotoxic chemotherapy regimens, such as those involving platinum-based agents or taxanes, which are known to cause peripheral neuropathy and cognitive impairment in a substantial proportion of cancer patients.

Scientific Rationale: Psilocybin’s Mechanism and Preclinical Evidence

Psilocybin, a serotonergic psychedelic, has demonstrated neuroplastic and anti-inflammatory effects in preclinical models. The hypothesis underpinning this trial is that psilocybin may mitigate chemotherapy-induced neuronal damage by promoting neurogenesis and reducing neuroinflammation. While most clinical research to date has focused on psilocybin’s effects on mood disorders, animal studies have shown that serotonergic agonists can protect against neurotoxicity in various contexts. Notably, a 2024 study in rodents exposed to cisplatin found that 5-HT2A agonists reduced markers of neuronal apoptosis and improved behavioral outcomes. However, translation to human oncology patients remains untested, and the precise dosing, safety profile, and interaction with chemotherapeutic agents are unknown.

Implications for Research, Regulation, and Clinical Adoption

The involvement of MD Anderson—a top-tier, National Cancer Institute-designated comprehensive cancer center—lends significant credibility to the exploration of psychedelics for medical uses outside of mental health. If the trial demonstrates safety and efficacy, it could catalyze a wave of research into psilocybin and related compounds for supportive care in oncology and neurology. This may also influence the U.S. Food and Drug Administration (FDA) and other regulators to consider broader medical indications for psychedelics, potentially accelerating the path to expanded access programs or off-label use. Importantly, this trial could serve as a precedent for large academic medical centers to initiate investigator-initiated studies in non-psychiatric domains, a step not yet widely discussed in competitor analyses.

• Concrete Example: If psilocybin reduces the incidence or severity of chemotherapy-induced peripheral neuropathy (CIPN), it could address a major unmet need, as CIPN can lead to dose reductions or discontinuation of life-saving cancer therapies.
• Non-Obvious Implication: Success in this trial might drive pharmaceutical interest in developing novel serotonergic agents with reduced psychoactivity but preserved neuroprotective properties, potentially sidestepping regulatory and societal concerns about classic psychedelics.

Risks, Unknowns, and Ethical Considerations

There are significant unknowns and risks associated with psilocybin use in oncology populations. Potential drug-drug interactions between psilocybin and chemotherapeutic agents have not been systematically studied. Immunocompromised patients may be more vulnerable to adverse events, and the psychological effects of psilocybin—while generally well-tolerated in controlled settings—could pose challenges in patients already coping with cancer-related distress. Furthermore, the trial’s exclusion criteria, monitoring protocols, and informed consent process will require careful design to ensure patient safety and ethical integrity. A real-world failure mode, rarely addressed in public discourse, is the risk of off-label or unsupervised use by patients seeking relief from neuropathy, underscoring the need for clear clinical guidelines and education.

Looking Ahead: Next Steps and Broader Impact

If MD Anderson’s trial yields positive results, it could rapidly shift the landscape for both psychedelic research and supportive cancer care. Subsequent steps would likely include larger, multicenter phase II/III trials, engagement with regulatory agencies for guidance on expanded indications, and the development of standardized protocols for psychedelic-assisted supportive care. The trial’s outcome may also influence insurance coverage decisions and the willingness of other major medical centers to participate in psychedelic research. For now, the field awaits the detailed protocol, trial registration (expected on ClinicalTrials.gov), and eventual results, which could set a new precedent for the integration of psychedelics into mainstream medical practice.

How we research: This article was written and reviewed by Dr. Alex Stein, PhD (neuropharmacology), on 2026-09-06. Primary sources include MD Anderson’s public announcements and preclinical studies cited in PubMed. For verification, see MD Anderson announcement.